$Oklo(OKLO.US) | Canaccord 维持对 Oklo 的买入评级,将目标价从 $125 下调至 $100
Oklo Inc. 开发裂变电厂,以大规模为美国客户提供能源。该公司提供的 Aurora Powerhouse 设计用于生产 15 到 75 兆瓦的电力。它还在商业化核燃料回收和燃料制造技术,这些技术可以将使用过的核燃料转化为其反应堆可用的燃料
Oklo 今日盘中大幅下跌,主因公司宣布启动 10 亿美元市价股票发行计划(ATM),由高盛、美银、花旗等十家机构担任销售代理,引发市场对稀释效应的担忧。该股盘中从 38.8 美元附近单边下行,最低触及 37.1 美元,跌幅约 6.9%,远低于 20 日均线 41.4 美元和 60 日均线 45.1 美元,年初至今已累计下跌 52.3%,距 52 周高点 193.8 美元回撤逾 80%。基本面方面,Q2 营收 121 万美元,净亏损 4854 万美元同比扩大 96.6%,每股亏损 0.28 美元,暂无盈利支撑。不过,Piper Sandler 此前给予买入评级,称其商业模式'具备银行可担保性',且当日盘后价格回升至 39.9 美元,显示部分买盘承接。
Oklo 今日盘中走弱,截至 ET 10:16 报 40.41 美元,较前收盘 42.57 下跌约 5.1%,盘中最低触及 40.41 创日内低点,而盘前曾一度高见 42.963。下跌主因来自高管持续减持的压力:CEO 及联合创始人 Jacob DeWitte 近期抛售 8 万股套现约 308 万美元(id:297827207),首席财务官亦卖出价值 63.68 万美元股票(id:297959598),引发市场对内部信心不足的担忧。上周该公司因美国陆军反应堆预算消息一度跌至近一月低位(id:297794684)。不过 Piper Sandler 新近给予买入评级,认为其商业模式「Bankable by Design」具备吸引力。从价格位置看,当前价较 52 周高点 193.84 美元回撤达 79.15%,YTD 跌幅 48.05%,且持续运行于 20 日均线 41.85 之下,短期技术面偏弱。
Oklo 今日盘中高开高走,截至 ET 09:36 报价 43.276 美元,较前收盘 41.27 美元上涨约 4.9%,创下日内高点 43.276 美元,而低点则出现在盘前的 41.29 美元,整体呈单边上行态势。驱动因素主要来自 AI 能源主题升温,相关报道提及核能作为 AI 基础设施的机遇,叠加入选美国能源部最新核能项目名单,提振市场情绪。不过,公司基本面仍处亏损状态,Q2 净亏损 4854 万美元,同比扩大 96.6%,且近期 CEO 及 CFO 均有减持行为,带来一定压力。当前价格较 52 周高点 193.84 美元仍低 77.7%,但站上 MA20(42.307 美元),YTD 累计下跌 44.4%。
Oklo 当日常规交易时段低开低走,截至 ET 09:34 报 38.61 美元,较前收盘 40.57 美元下跌约 4.8%,盘中最低触及 38.61 美元,创 52 周新低。盘前一度冲高至 40.892 美元后迅速回落,全天呈冲高回落走势。Q2 净亏损 4853.6 万美元,同比扩大 96.6%,每股亏损 0.2754 美元,营收仅 121 万美元,基本面持续承压。距 52 周高点 193.84 美元已跌去 80.1%,YTD 下跌 50.4%,当前股价低于 MA20(43.02 美元)及 MA60(47.11 美元),技术面维持弱势。不过,公司近期获美国能源部对 Groves 同位素试验堆项目的支持,商业化进程获正向催化。
OKLO.US 盘中单边下挫,截至 ET 11:57 报 40.36 美元,跌幅达 5.10%,回吐前两日涨幅。此次下跌主因是公司内部人士减持消息(id:297088222)引发市场担忧,叠加此前连续大涨后获利盘涌出,盘前即低开至 41.80 美元,盘中持续走弱并创日内新低 40.36 美元,低点较 52 周高位 193.84 美元跌去 79.18%,而当前价格仍低于 MA20(43.30 美元)和 MA60(47.85 美元),技术面偏弱。财报方面,Q2 净亏损 4853.6 万美元,同比扩大 96.62%,营收仅 121 万美元,商业化进程尚处早期。不过,公司近期获得 DOE 许可以及 FSG 支持 Groves 反应堆项目(id:296942735, id:296916424),为长期增长提供支撑。
📢 𝗝𝗨𝗦𝗧 𝗜𝗡: $Oklo(OKLO.US) Oklo Achieves First Criticality at Groves Test Reactor in Under One Year
👉 𝗞𝗲𝘆 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀:➤ 𝗢𝗸𝗹𝗼's 𝗚𝗿𝗼𝘃𝗲𝘀 𝗜𝘀𝗼𝘁𝗼𝗽𝗲 𝗧𝗲𝘀𝘁 𝗥𝗲𝗮𝗰𝘁𝗼𝗿 achieved first criticality.➤ Milestone was reached less than 𝟭 𝘆𝗲𝗮𝗿 after groundbreaking.➤ Reactor advanced under the 𝗨.𝗦. 𝗗𝗢𝗘 𝗥𝗲𝗮𝗰𝘁𝗼𝗿 𝗣𝗶𝗹𝗼𝘁 𝗣𝗿𝗼𝗴𝗿𝗮𝗺.➤ First RPP reactor to achieve criticality on 𝗽𝗿𝗶𝘃𝗮𝘁𝗲 𝗹𝗮𝗻𝗱 from a greenfield site.➤ Groves establishes the foundation for future 𝗰𝗼𝗺𝗺𝗲𝗿𝗰𝗶𝗮𝗹 𝗶𝘀𝗼𝘁𝗼𝗽𝗲 𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻.➤ Project demonstrates U.S. nuclear deployment can be measured in 𝗺𝗼𝗻𝘁𝗵𝘀, not years.➤ DOE authorization enabled parallel engineering, construction, and safety reviews.➤ Experience gained will support future 𝗶𝘀𝗼𝘁𝗼𝗽𝗲, 𝗽𝗼𝘄𝗲𝗿𝗵𝗼𝘂𝘀𝗲, and 𝗳𝘂𝗲𝗹 𝗰𝘆𝗰𝗹𝗲 deployments.➤ Groves supports domestic isotope production for healthcare, industry, space, and national security.👉 𝗪𝗵𝘆 𝗧𝗵𝗶𝘀 𝗠𝗮𝘁𝘁𝗲𝗿𝘀:➤ Validates Oklo's ability to rapidly deploy advanced nuclear technology.➤ Strengthens U.S. domestic isotope production and nuclear supply chain capabilities.➤ Demonstrates a faster regulatory pathway for advanced reactor commercialization.➤ Could accelerate investor confidence in next-generation nuclear energy deployment.👉 𝗘𝘅𝗽𝗲𝗿𝘁 𝗦𝘁𝗮𝘁𝗲𝗺𝗲𝗻𝘁𝘀:𝗝𝗮𝗰𝗼𝗯 𝗗𝗲𝘄𝗶𝘁𝘁𝗲, Co-founder and CEO of Oklo:“Reaching criticality in less than a year is an incredible milestone for our team. Oklo developed Groves from a greenfield site on private land, completed full-scale civil excavation and construction, manufactured or commercially procured all components, including fuel, and developed its operating programs in-house. Taken together, we believe these accomplishments establish a new benchmark for the Reactor Pilot Program and set the stage for the future of advanced nuclear deployment at scale.”𝗧𝗲𝗱 𝗚𝗮𝗿𝗿𝗶𝘀𝗵, Assistant Secretary for Nuclear Energy:"Thanks to President Trump's precedent-setting directive to create the Reactor Pilot Program, Oklo's Groves Isotope Test Reactor is part of the revival of America's nuclear energy industry. We applaud the work of the Oklo, DOE, and Idaho National Laboratory staff who helped achieve this milestone."𝗚𝗼𝘃𝗲𝗿𝗻𝗼𝗿 𝗚𝗿𝗲𝗴 𝗔𝗯𝗯𝗼𝘁𝘁, Governor of Texas:“Texas is leading America’s nuclear renaissance by advancing the technologies that will power innovation and strengthen our nation's future. From expanding our nuclear workforce to rebuilding critical domestic supply chains, Texas is creating the foundation for the next generation of advanced nuclear development. Congratulations to Oklo on reaching this important milestone, which will help expand isotope production for critical medical therapies and reinforce Texas' leadership in nuclear innovation.”